发明名称 Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
摘要 The present invention relates to antibody-drug conjugate compounds of Formula I: Ab-(L-D)p  Iwhere one or more nemorubicin metabolite or analog drug moieties (D) are covalently attached by a linker (L) to an antibody (Ab) which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be useful in methods of diagnosis or treatment of cancer, and other diseases and disorders.
申请公布号 US8742076(B2) 申请公布日期 2014.06.03
申请号 US20090865354 申请日期 2009.01.16
申请人 Genentech, Inc. 发明人 Cohen Robert L.;Ha Edward HyungSuk;Reynolds Mark E.
分类号 C07K16/00;C07K14/00;A61K39/00 主分类号 C07K16/00
代理机构 代理人
主权项 1. An antibody-drug conjugate compound selected from the structures: wherein p is 1, 2, 3, 4, 5, 6, 7, or 8; and Ab is an antibody which binds to one or more tumor-associated antigens or cell-surface receptors selected from (1)-(36): (1) BMPR1B (bone morphogenetic protein receptor-type IB), (2) E16 (LAT1, SLC7A5), (3) STEAP1 (six transmembrane epithelial antigen of prostate), (4) 0772P (CA125, MUC16), (5) MPF (MPF, MSLN, SMR, megakaryocyte potentiating factor, mesothelin), (6) Napi3b (NAPI-3B, NPTIIb, SLC34A2, solute carrier family 34 (sodium phosphate), member 2, type II sodium-dependent phosphate transporter 3b), (7) Sema 5b (FLJ10372, KIAA1445, Mm.42015, SEMA5B, SEMAG, Semaphorin 5b Hlog, sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5B), (8) PSCA hlg (2700050C12Rik, C530008O16Rik, RIKEN cDNA 2700050C12, RIKEN cDNA 2700050C12 gene), (9) ETBR (Endothelin type B receptor), (10) MSG783 (RNF124, hypothetical protein FLJ20315), (11) STEAP2 (HGNC—8639, IPCA-1, PCANAP1, STAMP1, STEAP2, STMP, prostate cancer associated gene 1, prostate cancer associated protein 1, six transmembrane epithelial antigen of prostate 2, six transmembrane prostate protein), (12) TrpM4 (BR22450, FLJ20041, TRPM4, TRPM4B, transient receptor potential cation channel, subfamily M, member 4), (13) CRIPTO (CR, CR1, CRGF, CRIPTO, TDGF1, teratocarcinoma-derived growth factor), (14) CD21 (CR2 (Complement receptor 2) or C3DR (C3d/Epstein Barr virus receptor) or Hs 73792), (15) CD79b (CD79B, CD79β, IGb (immunoglobulin-associated beta), B29), (16) FcRH2 (IFGP4, IRTA4, SPAP1A (SH2 domain containing phosphatase anchor protein 1a), SPAP1B, SPAP1C), (17) HER2, (18) NCA, (19) MDP, (20) IL20Rα, (21) Brevican, (22) EphB2R, (23) ASLG659, (24) PSCA, (25) GEDA, (26) BAFF-R (B cell-activating factor receptor, BLyS receptor 3, BR3), (27) CD22 (B-cell receptor CD22-B isoform), (28) CD79a (CD79A, CD79α, immunoglobulin-associated alpha), (29) CXCR5 (Burkitt's lymphoma receptor 1), (30) HLA-DOB (Beta subunit of MHC class II molecule (Ia antigen)), (31) P2X5 (Purinergic receptor P2X ligand-gated ion channel 5), (32) CD72 (B-cell differentiation antigen CD72, Lyb-2), (33) LY64 (Lymphocyte antigen 64 (RP105), type I membrane protein of the leucine rich repeat (LRR) family), (34) FcRH1 (Fc receptor-like protein 1), (35) IRTA2 (Immunoglobulin superfamily receptor translocation associated 2), and (36) TENB2 (putative transmembrane proteoglycan).
地址 South San Francisco CA US
您可能感兴趣的专利